MAP2K7 and metastatic melanoma: For patients diagnosed with BRAF-mutated metastatic melanoma exhibiting extensive and symptomatic disease, the preferred initial treatment approach is to initiate targeted therapy utilizing BRAF and MEK inhibitors.